Results 121 to 130 of about 53,090 (292)
Identification of cancer-specific cell surface targets for CAR-T cell therapy
Inflammation and RegenerationOne should identify appropriate cell surface targets to develop new CAR-T cells. Currently, lineage-specific antigens such as CD19 or B cell maturation antigen (BCMA) are being used as targets for CAR-T cells.
Naoki Hosen
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu +6 more
wiley +1 more source
CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases? [PDF]
Autoimmune rheumatic diseases (ARDs), such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, involve dysregulated immune responses causing chronic inflammation and tissue damage.
José Luis Callejas +6 more
core +1 more source
Comparison of Tissue Preparations to Identify and Phenotype T Cells in Human Colorectal Tumor Tissue
Cytometry Part A, EarlyView.ABSTRACT Archived patient samples (e.g., formalin‐fixed paraffin embedded (FFPE) tissue blocks, cryoembedded tissue blocks, and frozen whole tissue samples) are a source of immune information for which corresponding patient data is often collected.
Justin F. Tirados +5 more
wiley +1 more source
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley +1 more source
Current progress in chimeric antigen receptor T‐cell therapy for malignant tumors
MedComm – Future MedicineIn the realm of malignant tumor treatment, particularly regarding hematologic malignancies, chimeric antigen receptor T‐cell (CAR‐T) immunotherapy has witnessed remarkable advancements in recent years.
Yashang Zheng +3 more
doaj +1 more source
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma
Frontiers in PediatricsClinical trials of anti-CD19 chimeric antigen receptor T (CART19) cell therapy have shown high overall response rates in patients with relapsed/refractory B-cell malignancies.
Shuto Negishi +10 more
doaj +1 more source
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Our knowledge of the immune system continues to expand at a rapid pace, and this coupled with technological advances now enables us to interrogate both the breadth and the depth of the immune response at levels without precedent. This has also facilitated rapidly integrating some of this carefully vetted knowledge into clinical practice ...
Aaruni Khanolkar, Aisha Ahmed
wiley +1 more source
Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications
Barrier Immunity, EarlyView.A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu +9 more
wiley +1 more source